A Phase 3 interventional study of Tislelizumab and Placebo in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Completed at 33 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by BeiGene · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma — 13 open to participants now, 15 under way, 1 of them phase 3. tislelizumab · Esophageal Squamous Cell Carcinoma.
Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 3 in phase 3, and was the 3rd registered.
676 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →13 of the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma are open now, in 4 countries. Recruiting first, the newest first:
BeOne Medicines · Sites in Japan
Ages 18+
BeOne Medicines · Sites in United States
Ages 18+
Ming-Yu Lien · Sites in Taiwan
Ages 20+
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Sichuan University · Sites in China
Ages 18–75
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 4 · Phase 4 1
First in 2018; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 370 is above the median of 64 across 564 interventional studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 50 across the 23 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
10 studies in Esophageal Squamous Cell Carcinoma by BeOne Medicines: 2 open now, 2 under way, none of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 10 studies in Esophageal Squamous Cell Carcinoma by BeOne Medicines, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 3 in phase 3, and was the 4th registered.
BeOne Medicines’s Esophageal Squamous Cell Carcinoma studies by the year they started, since 2017.
1 of the studies testing tislelizumab in Esophageal Squamous Cell Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07317609Shanghai Zhongshan HospitalNeoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BeOne Medicines’s 10 in Esophageal Squamous Cell Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 3, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of tislelizumab (BGB-A317) versus placebo in combination with chemoradiotherapy in participants with localized esophageal squamous cell carcinoma (ESCC).
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 mg tislelizumab administered intravenously (IV) once every 3 weeks in combination with concurrent chemoradiotherapy (CRT) for up to approximately 6 weeks followed by 200 mg tislelizumab for a total of up to 24 months (about 35 cycles), or until disease progression, unacceptable toxicity, withdrawal of consent, or another treatment discontinuation criterion was met, whichever occurred first. Concurrent chemotherapy consisted of cisplatin (25 mg/m² IV; Days 1-3 of each 3-week cycle) in combination with paclitaxel (135 mg/m² IV; Day 1 of each 3-week cycle) and radiotherapy was delivered in 28 fractions (total dose, 50.4 Gy).
Drug: Tislelizumab · Drug: Paclitaxel · Drug: Cisplatin · Radiation: Radiotherapy
Participants received placebo IV once every 3 weeks in combination with concurrent chemoradiotherapy (CRT) for up to approximately 6 weeks followed by placebo for a total of up to 24 months (about 35 cycles), or until disease progression, unacceptable toxicity, withdrawal of consent, or another treatment discontinuation criterion was met, whichever occurred first. Concurrent chemotherapy consisted of cisplatin (25 mg/m² IV; Days 1-3 of each 3-week cycle) in combination with paclitaxel (135 mg/m² IV; Day 1 of each 3-week cycle) and radiotherapy was delivered in 28 fractions (total dose, 50.4 Gy).
Drug: Placebo · Drug: Paclitaxel · Drug: Cisplatin · Radiation: Radiotherapy
Administered intravenously (IV)
Also known as: BGB-A317, Tevimbra
Placebo to match tislelizumab administered intravenously
Administered as 135 mg/m² IV injection
Administered as 25 mg/m² IV injection
Administered at a total dose of 50.4 Gy in 28 fractions
Progression-free Survival (PFS)
PFS is defined as the time from randomization to the first documented disease progression, as determined by the Blinded Independent Review Committee (BIRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death from any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, and an absolute increase of at least 5 mm, and/or unequivocal progression of existing nontarget lesions. or the appearance of one or more new lesions.
Time frame: From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.
Overall Survival (OS)
OS is defined as the time from the date of randomization to the date of death due to any cause. OS was estimated using the Kaplan-Meier method.
Time frame: From randomization to the prespecified analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Oesophageal Cancer Module (OES18) Dysphagia, Reflux, Pain, and Eating Scales
The EORTC-QLQ-OES18 is the specific esophageal symptoms module of the QLQ-C30. QLQ-OES18 is comprised of 18 questions grouped into 4 multi-item subscales: Dysphagia (3 items), Eating (4 items), Reflux (2 items), and Pain (3 items) and 6 single item subscales (saliva swallowing, choking, dry mouth, taste, coughing, and talking). Participants indicate the extent to which they have experienced symptoms on a scale from 1 (Not at all) to 4 (Very much). Scores are calculated and transformed to a scale from 0 to 100; higher scores indicate a higher level of symptomatology or problems.
Time frame: Baseline and Cycle 6 and Cycle 10 (each cycle was 21 days)
Change From Baseline in EORTC Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL), Physical Functioning, and Fatigue Scores
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life. Lower scores in symptom scales indicate better quality of life.
Time frame: Baseline and Cycle 6 and Cycle 10 (each cycle was 21 days)
Overall Response Rate (ORR)
ORR is defined as the percentage of participants who had complete response (CR) or partial response (PR) as assessed by BIRC per RECIST v1.1. Tumor assessments were made using computed tomography (CT) scans or using magnetic resonance imaging (MRI). CR: Disappearance of all target lesions and non-target lesions, no new lesions, and normalization of tumor marker level. All lymph nodes must be nonpathological in size (\<10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters and/or persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.
Time frame: Tumor assessments occurred every 9 weeks for the first 54 weeks, and every 12 weeks during the next 2 years and every 24 weeks thereafter until radiographic disease progression or death; up to 67 months
Duration of Response (DOR)
DOR is defined as the time from the first occurrence of a documented objective response to the time of relapse, as determined by the BIRC per RECIST v1.1, or death from any cause, whichever occurs first. DOR was estimated using the Kaplan-Meier method.
Time frame: Up to 67 months
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment, whether considered related to study treatment or not. A TEAE is an AE that had an onset date or a worsening in severity from baseline on or after the first dose of study treatment and up to 30 days following study treatment discontinuation or initiation of new anticancer therapy, whichever occurred first. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement.
Time frame: From first dose of study drug to 30 days after last dose, maximum time on treatment was 57.5 months
This study was conducted at 32 centers in China.
| Milestone | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy |
|---|---|---|
| Started | 185 | 185 |
| Received study drug | 185 | 184 |
| Completed | 0 | 0 |
| Not completed | 185 | 185 |
| Withdrew: Death | 100 | 93 |
| Withdrew: Sponsor ended study | 83 | 91 |
| Withdrew: Withdrawal by subject | 2 | 1 |
PFS is defined as the time from randomization to the first documented disease progression, as determined by the Blinded Independent Review Committee (BIRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death from any cause, whichever occurred first. PFS was estimated using the Kaplan-Meier method. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, and an absolute increase of at least 5 mm, and/or unequivocal progression of existing nontarget lesions. or the appearance of one or more new lesions.
| months | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy |
|---|---|---|
| Progression-free Survival (PFS) | 29.0 (18.8 to NA) | 28.9 (18.0 to NA) |
OS is defined as the time from the date of randomization to the date of death due to any cause. OS was estimated using the Kaplan-Meier method.
| months | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy |
|---|---|---|
| Overall Survival (OS) | 39.2 (28.3 to NA) | 48.2 (30.2 to NA) |
The EORTC-QLQ-OES18 is the specific esophageal symptoms module of the QLQ-C30. QLQ-OES18 is comprised of 18 questions grouped into 4 multi-item subscales: Dysphagia (3 items), Eating (4 items), Reflux (2 items), and Pain (3 items) and 6 single item subscales (saliva swallowing, choking, dry mouth, taste, coughing, and talking). Participants indicate the extent to which they have experienced symptoms on a scale from 1 (Not at all) to 4 (Very much). Scores are calculated and transformed to a scale from 0 to 100; higher scores indicate a higher level of symptomatology or problems.
| score on a scale | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy |
|---|---|---|
| Dysphagia at Cycle 6 | 4.2 (0.1 to 8.3) | 7.1 (3.1 to 11.1) |
| Dysphagia at Cycle 10 | 8.8 (4.6 to 13.0) | 7.6 (3.5 to 11.7) |
| Reflux at Cycle 6 | -4.3 (-5.9 to -2.7) | -4.5 (-6.1 to -3.0) |
| Reflux at Cycle 10 | -4.9 (-6.7 to -3.1) | -4.2 (-5.9 to -2.4) |
| Pain at Cycle 6 | -3.7 (-5.5 to -2.0) | -3.4 (-5.1 to -1.6) |
| Pain at Cycle 10 | -5.4 (-6.9 to -3.9) | -4.8 (-6.2 to -3.3) |
| Eating at Cycle 6 | -5.3 (-7.4 to -3.3) | -6.3 (-8.3 to -4.3) |
| Eating at Cycle 10 | -5.8 (-8.0 to -3.6) | -7.8 (-9.9 to -5.7) |
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life. Lower scores in symptom scales indicate better quality of life.
| score on a scale | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy |
|---|---|---|
| GHS/QoL at Cycle 6 | 2.461 ± 17.6113 | 1.572 ± 18.6143 |
| GHS/QoL at Cycle 10 | 4.104 ± 16.0012 | 2.778 ± 19.2278 |
| Physical Functioning at Cycle 6 | -2.864 ± 15.0526 | 0.294 ± 12.1488 |
| Physical Functioning at Cycle 10 | 0.101 ± 9.6058 | 2.506 ± 10.6470 |
| Fatigue at Cycle 6 | 2.013 ± 17.6655 | -0.280 ± 15.8101 |
| Fatigue at Cycle 10 | 0.926 ± 15.9540 | -2.679 ± 17.4119 |
ORR is defined as the percentage of participants who had complete response (CR) or partial response (PR) as assessed by BIRC per RECIST v1.1. Tumor assessments were made using computed tomography (CT) scans or using magnetic resonance imaging (MRI). CR: Disappearance of all target lesions and non-target lesions, no new lesions, and normalization of tumor marker level. All lymph nodes must be nonpathological in size (\<10 mm short axis). PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters and/or persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.
| percentage of participants | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy |
|---|---|---|
| Overall Response Rate (ORR) | 27.6 (21.3 to 34.6) | 38.9 (31.9 to 46.3) |
DOR is defined as the time from the first occurrence of a documented objective response to the time of relapse, as determined by the BIRC per RECIST v1.1, or death from any cause, whichever occurs first. DOR was estimated using the Kaplan-Meier method.
| months | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy |
|---|---|---|
| Duration of Response (DOR) | NA (NA to NA) | NA (41.4 to NA) |
An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment, whether considered related to study treatment or not. A TEAE is an AE that had an onset date or a worsening in severity from baseline on or after the first dose of study treatment and up to 30 days following study treatment discontinuation or initiation of new anticancer therapy, whichever occurred first. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgement.
| Participants | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy |
|---|---|---|
| Any adverse event | 185 | 184 |
| Serious Adverse events | 84 | 63 |
Collected over Deaths are reported up to the end of the study, maximum time on study was 68.5 months. Adverse events were collected from first dose of study drug to 30 days after last dose, maximum time on treatment was 57.5 months.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tislelizumab + Chemoradiotherapy | 100/185 (54.1%) | 84/185 (45.4%) | 185/185 (100%) |
| Placebo + Chemoradiotherapy | 93/185 (50.3%) | 63/184 (34.2%) | 184/184 (100%) |
| Event | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy |
|---|---|---|
| PneumoniaInfections and infestations | 20/185 | 8/184 |
| Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders | 14/185 | 2/184 |
| Platelet count decreasedInvestigations | 6/185 | 3/184 |
| Oesophageal fistulaGastrointestinal disorders | 1/185 | 5/184 |
| Oesophageal obstructionGastrointestinal disorders | 5/185 | 5/184 |
| Radiation oesophagitisInjury, poisoning and procedural complications | 1/185 | 5/184 |
| White blood cell count decreasedInvestigations | 3/185 | 5/184 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 2/185 | 4/184 |
| Cerebral infarctionNervous system disorders | 1/185 | 4/184 |
| DysphagiaGastrointestinal disorders | 4/185 | 1/184 |
| Event | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy |
|---|---|---|
| White blood cell count decreasedInvestigations | 147/185 | 150/184 |
| AnaemiaBlood and lymphatic system disorders | 139/185 | 138/184 |
| Neutrophil count decreasedInvestigations | 126/185 | 136/184 |
| Radiation oesophagitisInjury, poisoning and procedural complications | 86/185 | 93/184 |
| NauseaGastrointestinal disorders | 89/185 | 75/184 |
| Platelet count decreasedInvestigations | 89/185 | 84/184 |
| Weight decreasedInvestigations | 84/185 | 59/184 |
| Lymphocyte count decreasedInvestigations | 65/185 | 70/184 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 66/185 | 69/184 |
| ConstipationGastrointestinal disorders | 67/185 | 66/184 |
| Age, Categorical(Participants) | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 86 | 84 | 170 |
| >=65 years | 99 | 101 | 200 |
| Age, Continuous(years) | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy | Total |
|---|---|---|---|
| Median | 65.0 (46 to 75) | 65.0 (46 to 75) | 65.0 (46 to 75) |
| Sex: Female, Male(Participants) | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy | Total |
|---|---|---|---|
| Female | 32 | 24 | 56 |
| Male | 153 | 161 | 314 |
| Race (NIH/OMB)(Participants) | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 185 | 185 | 370 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy | Total |
|---|---|---|---|
| 0 (Fully Active) | 78 | 78 | 156 |
| 1 (Ambulatory with Restricted Activity) | 107 | 107 | 214 |
| Clinical Stage(Participants) | Tislelizumab + Chemoradiotherapy | Placebo + Chemoradiotherapy | Total |
|---|---|---|---|
| Stage II | 44 | 42 | 86 |
| Stage III | 96 | 97 | 193 |
| Stage IVa | 45 | 45 | 90 |
| Stage IVb | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beigene.com
Ran from Jun 2019 to primary completion in Jan 2025, 66 months.
Results were first posted in Apr 2026, 1 year 3 months after primary completion.
Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's 66 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab
Esophageal Squamous Cell Carcinoma →